hdacin6

Fluoxetine succinate ester is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder.

HDAC-IN-6 is an HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9.

HDAC-IN-65 (compound 6) is a selective histone deacetylase (HDAC) inhibitor with an IC50 value of 2.5 μM. It is a prodrug offering excellent bioreductive properties.

HDAC-IN-66 (compound 2F) is a selective inhibitor of HDAC and a derivative of Pomalidomide, effectively inhibiting hematological tumor cells.

HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structures and suppresses tumor growth. This compound notably inhibits class I HDACs, specifically HDAC1, HDAC2, and HDAC3, with IC50 values of 5.1, 11.5, and 8.8 nM, respectively.

HDAC-IN-68 (hydrochloride) (Compound 29) is an HDACs inhibitor with an IC50 value of 0.04 μM and induces microtubule fragmentation by activating katanin, a microtubule-severing protein. It is applicable in cancer research.

HDAC-IN-60 (compound 21a), a potent histone deacetylase (HDAC) inhibitor, promotes intracellular reactive oxygen species (ROS) production, induces DNA damage, arrests the cell cycle at the G2/M phase, and triggers mitochondria-related apoptotic pathways, leading to cell apoptosis [1].

HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1. It effectively suppresses MV4-11 cell proliferation (IC50 of 92 nM), induces apoptosis, and arrests the cell cycle in MV4-11 cells. This compound is applied in acute myeloid leukemia (AML) research [1].

HDAC-IN-62 (Compound 5), an HDAC inhibitor, exhibits IC50 values of 0.78, 1.0, and 1.2 μM for HDAC6, HDAC8, and HDAC11, respectively. This compound suppresses microglial activation via autophagy induction and reduces nitric oxide production, demonstrating anti-inflammatory and antidepressant properties. Additionally, HDAC-IN-62 has been shown to inhibit microglial activation in mouse brains [1].

HDAC-IN-61 (compound 12k) is a potent, orally active histone deacetylase (HDAC) inhibitor with anticancer activity, exhibiting an IC50 of 30 nM against Bel-7402 cells and is utilized for cancer research [1].

HDAC-IN-64 (Compound 13), an HDAC inhibitor, demonstrates potent inhibition of HDAC4/5/6/7/9 with IC50 values of 24, 45, 85, 31, and 37 nM, respectively. It exhibits anti-proliferative and anti-migration effects on prostate cancer (PCA) cells, specifically inhibiting the growth of LNCaP and RWPE-1 cells with GI50 values of 0.32 and 1.1 μM, respectively [1].

HDAC-IN-67 (compound 27f) acts as an inhibitor of HDAC1 and HDAC6, demonstrating IC50 values of 22 nM and 8 nM, respectively. This compound effectively inhibits cell proliferation and triggers apoptosis, while also displaying antitumor activity [1].